|
|
||||||||
J. Biol. Chem., Vol. 279, Issue 49, 51630-51646, December 3, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Departments of aMolecular Pharmacology and Medicine, ePathology, and iCell Biology and Medicine, Albert Einstein College of Medicine and the bAlbert Einstein Cancer Center, Bronx, New York 10461, the fWhitehead Institute for Biomedical Research, Cambridge, Massachussetts 02142 the gDepartment of Medicine and Biochemistry, McGill University, Montreal, Quebec H3G 1Y6, Canada, the hDepartment of Pathology, Jacobi Medical Center, Bronx, New York 10461, and the kDepartment of Oncology, Lombardi Cancer Center, Georgetown University, Washington, D. C. 20007
Caveolin-1 (Cav-1) is the principal structural component of caveolae membrane domains in non-muscle cells, including mammary epithelia. There is now clear evidence that caveolin-1 influences the development of human cancers. For example, a dominant-negative mutation (P132L) in the Cav-1 gene has been detected in up to 16% of human breast cancer samples. However, the exact functional role of caveolin-1 remains controversial. Mechanistically, in cultured cell models, Cav-1 is known to function as a negative regulator of the Rasp42/44 MAP kinase cascade and as a transcriptional repressor of cyclin D1 gene expression, possibly explaining its in vitro transformation suppressor activity. Genetic validation of this hypothesis at the in vivo and whole organismal level has been prevented by the lack of a Cav-1 (-/-)-null mouse model. Here, we examined the role of caveolin-1 in mammary tumorigenesis and lung metastasis using a molecular genetic approach. We interbred a well characterized transgenic mouse model of breast cancer, MMTV-PyMT (mouse mammary tumor virus-polyoma middle T antigen), with Cav-1 (-/-)-null mice. Then, we followed the onset and progression of mammary tumors and lung metastases in female mice over a 14-week period. Interestingly, PyMT/Cav-1 (-/-) mice showed an accelerated onset of mammary tumors, with increased multiplicity and tumor burden (
2-fold). No significant differences were detected between PyMT/Cav-1 (+/+) and PyMT/Cav-1 (+/-) mice, indicating that complete loss of caveolin-1 is required to accelerate both tumorigenesis and metastasis. Molecularly, mammary tumor samples derived from PyMT/Cav-1 (-/-) mice showed ERK-1/2 hyperactivation, cyclin D1 up-regulation, and Rb hyperphosphorylation, consistent with dys-regulated cell proliferation. PyMT/Cav-1 (-/-) mice also developed markedly advanced metastatic lung disease. Conversely, recombinant expression of Cav-1 in a highly metastatic PyMT mammary carcinoma-derived cell line, namely Met-1 cells, suppressed lung metastasis by
4.5-fold. In vitro, these Cav-1-expressing Met-1 cells (Met-1/Cav-1) demonstrated a
4.8-fold reduction in invasion through Matrigel-coated membranes. Interestingly, delivery of a cell permeable peptide encoding the caveolin-1 scaffolding domain (residues 82-101) into Met-1 cells was sufficient to inhibit invasion. Coincident with this decreased invasive index, Met-1/Cav-1 cells exhibited marked reductions in MMP-9 and MMP-2 secretion and associated gelatinolytic activity, as well as diminished ERK-1/2 signaling in response to growth factor stimulation. These results demonstrate, for the first time, that caveolin-1 is a potent suppressor of mammary tumor growth and metastasis using novel in vivo animal model approaches.
Received for publication, August 11, 2004
* This work was supported in part by grants from the National Institutes of Health (NIH), the Susan G. Komen Breast Cancer Foundation, as well as Hirschl/Weil-Caulier Career Scientist Award (all to M. P. L.). Work conducted at the Lombardi Cancer Center was supported by Comprehensive Cancer Center Core National Institute of Health Grant P30 CA51008-13. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
c Supported by a National Institutes of Health Medical Scientist Training Grant (T32-GM07288).
d Supported by an NIH Graduate Training Program Grant (T32-DK07513).
j Supported by Grant R01-DK55758 from the NIH and the Komen Breast Cancer Foundation.
l Supported by Grants R01CA70896, R01CA75503, R01CA86072 from the NIH.
m To whom correspondence should be addressed. Tel.: 718-430-8828; Fax: 718-430-8830; E-mail: lisanti{at}aecom.yu.edu.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
L. C. Matthews, M. J. Taggart, and M. Westwood Modulation of Caveolin-1 Expression Can Affect Signalling through the Phosphatidylinositol 3-Kinase/Akt Pathway and Cellular Proliferation in Response to Insulin-Like Growth Factor I Endocrinology, October 1, 2008; 149(10): 5199 - 5208. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Mamillapalli, J. VanHouten, W. Zawalich, and J. Wysolmerski Switching of G-protein Usage by the Calcium-sensing Receptor Reverses Its Effect on Parathyroid Hormone-related Protein Secretion in Normal Versus Malignant Breast Cells J. Biol. Chem., September 5, 2008; 283(36): 24435 - 24447. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. R. Lizarbe, C. Garcia-Rama, C. Tarin, M. Saura, E. Calvo, J. A. Lopez, C. Lopez-Otin, A. R. Folgueras, S. Lamas, and C. Zaragoza Nitric oxide elicits functional MMP-13 protein-tyrosine nitration during wound repair FASEB J, September 1, 2008; 22(9): 3207 - 3215. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Wakamatsu, J. B. Collins, J. S. Parker, M. Tessema, N. P. Clayton, T.-V. T. Ton, H.-H. L. Hong, S. Belinsky, T. R. Devereux, R. C. Sills, et al. Gene Expression Studies Demonstrate that the K-ras/Erk MAP Kinase Signal Transduction Pathway and Other Novel Pathways Contribute to the Pathogenesis of Cumene-induced Lung Tumors Toxicol Pathol, July 1, 2008; 36(5): 743 - 752. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Bifulco, A. M. Malfitano, S. Pisanti, and C. Laezza Endocannabinoids in endocrine and related tumours Endocr. Relat. Cancer, June 1, 2008; 15(2): 391 - 408. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Wu, S. Katiyar, A. Li, M. Liu, X. Ju, V. M. Popov, X. Jiao, M. P. Lisanti, A. Casola, and R. G. Pestell Dachshund inhibits oncogene-induced breast cancer cellular migration and invasion through suppression of interleukin-8 PNAS, May 13, 2008; 105(19): 6924 - 6929. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Bianco, L. Strizzi, M. Mancino, K. Watanabe, M. Gonzales, S. Hamada, A. Raafat, L. Sahlah, C. Chang, F. Sotgia, et al. Regulation of Cripto-1 Signaling and Biological Activity by Caveolin-1 in Mammary Epithelial Cells Am. J. Pathol., February 1, 2008; 172(2): 345 - 357. [Abstract] [Full Text] [PDF] |
||||
![]() |
X.-q. Wang, Q. Yan, P. Sun, J.-W. Liu, L. Go, S. M. McDaniel, and A. S. Paller Suppression of Epidermal Growth Factor Receptor Signaling by Protein Kinase C-{alpha} Activation Requires CD82, Caveolin-1, and Ganglioside Cancer Res., October 15, 2007; 67(20): 9986 - 9995. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Cantiani, M. C. Manara, C. Zucchini, P. De Sanctis, M. Zuntini, L. Valvassori, M. Serra, M. Olivero, M. F. Di Renzo, M. P. Colombo, et al. Caveolin-1 Reduces Osteosarcoma Metastases by Inhibiting c-Src Activity and Met Signaling Cancer Res., August 15, 2007; 67(16): 7675 - 7685. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Veiseh, P. Gabikian, S-B. Bahrami, O. Veiseh, M. Zhang, R. C. Hackman, A. C. Ravanpay, M. R. Stroud, Y. Kusuma, S. J. Hansen, et al. Tumor Paint: A Chlorotoxin:Cy5.5 Bioconjugate for Intraoperative Visualization of Cancer Foci Cancer Res., July 15, 2007; 67(14): 6882 - 6888. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Costa, M. Senou, F. Van Rode, J. Ruf, M. Capello, D. Dequanter, P. Lothaire, C. Dessy, J. E. Dumont, M.-C. Many, et al. Reciprocal Negative Regulation between Thyrotropin/3',5'-Cyclic Adenosine Monophosphate-Mediated Proliferation and Caveolin-1 Expression in Human and Murine Thyrocytes Mol. Endocrinol., April 1, 2007; 21(4): 921 - 932. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Song, S. Ge, and J. S. Pachter Caveolin-1 regulates expression of junction-associated proteins in brain microvascular endothelial cells Blood, February 15, 2007; 109(4): 1515 - 1523. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-I. Kwak, T. Gustafson, R. P. Metz, B. Laffin, P. Schedin, and W. W. Porter Inhibition of breast cancer growth and invasion by single-minded 2s Carcinogenesis, February 1, 2007; 28(2): 259 - 266. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Sotgia, H. Rui, G. Bonuccelli, I. Mercier, R. G. Pestell, and M. P. Lisanti Caveolin-1, Mammary Stem Cells, and Estrogen-Dependent Breast Cancers. Cancer Res., November 15, 2006; 66(22): 10647 - 10651. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. M. Williams, F. Sotgia, H. Lee, G. Hassan, D. Di Vizio, G. Bonuccelli, F. Capozza, I. Mercier, H. Rui, R. G. Pestell, et al. Stromal and Epithelial Caveolin-1 Both Confer a Protective Effect Against Mammary Hyperplasia and Tumorigenesis: Caveolin-1 Antagonizes Cyclin D1 Function in Mammary Epithelial Cells Am. J. Pathol., November 1, 2006; 169(5): 1784 - 1801. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. M. Tirado, S. Mateo-Lozano, J. Villar, L. E. Dettin, A. Llort, S. Gallego, J. Ban, H. Kovar, and V. Notario Caveolin-1 (CAV1) Is a Target of EWS/FLI-1 and a Key Determinant of the Oncogenic Phenotype and Tumorigenicity of Ewing's Sarcoma Cells. Cancer Res., October 15, 2006; 66(20): 9937 - 9947. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Cabrita, F. Jaggi, S. P. Widjaja, and G. Christofori A Functional Interaction between Sprouty Proteins and Caveolin-1 J. Biol. Chem., September 29, 2006; 281(39): 29201 - 2912. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Chetty, P. Bhoopathi, P. Joseph, S. Chittivelu, J. S. Rao, and S. Lakka Adenovirus-mediated small interfering RNA against matrix metalloproteinase-2 suppresses tumor growth and lung metastasis in mice. Mol. Cancer Ther., September 1, 2006; 5(9): 2289 - 2299. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Nozawa, C. Chiu, and D. Hanahan Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis PNAS, August 15, 2006; 103(33): 12493 - 12498. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Zhang, K. Furukawa, H.-H. Chen, T. Sakakibara, T. Urano, and K. Furukawa Metastatic Potential of Mouse Lewis Lung Cancer Cells Is Regulated via Ganglioside GM1 by Modulating the Matrix Metalloprotease-9 Localization in Lipid Rafts J. Biol. Chem., June 30, 2006; 281(26): 18145 - 18155. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Li, F. Sotgia, M. A. Vuolo, M. Li, W. C. Yang, R. G. Pestell, J. A. Sparano, and M. P. Lisanti Caveolin-1 Mutations in Human Breast Cancer: Functional Association with Estrogen Receptor {alpha}-Positive Status Am. J. Pathol., June 1, 2006; 168(6): 1998 - 2013. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. S. Hassan, T. M. Williams, P. G. Frank, and M. P. Lisanti Caveolin-1-deficient aortic smooth muscle cells show cell autonomous abnormalities in proliferation, migration, and endothelin-based signal transduction Am J Physiol Heart Circ Physiol, June 1, 2006; 290(6): H2393 - H2401. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Schwencke, R. C. Braun-Dullaeus, C. Wunderlich, and R. H. Strasser Caveolae and caveolin in transmembrane signaling: Implications for human disease Cardiovasc Res, April 1, 2006; 70(1): 42 - 49. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Konopleva, W. Zhang, Y.-X. Shi, T. McQueen, T. Tsao, M. Abdelrahim, M. F. Munsell, M. Johansen, D. Yu, T. Madden, et al. Synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest in HER2-overexpressing breast cancer cells. Mol. Cancer Ther., February 1, 2006; 5(2): 317 - 328. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Sotgia, T. M. Williams, W. Schubert, F. Medina, C. Minetti, R. G. Pestell, and M. P. Lisanti Caveolin-1 Deficiency (-/-) Conveys Premalignant Alterations in Mammary Epithelia, with Abnormal Lumen Formation, Growth Factor Independence, and Cell Invasiveness Am. J. Pathol., January 1, 2006; 168(1): 292 - 309. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Miotti, A. Tomassetti, I. Facetti, E. Sanna, V. Berno, and S. Canevari Simultaneous Expression of Caveolin-1 and E-Cadherin in Ovarian Carcinoma Cells Stabilizes Adherens Junctions through Inhibition of src-Related Kinases Am. J. Pathol., November 1, 2005; 167(5): 1411 - 1427. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. M. Williams, G. S. Hassan, J. Li, A. W. Cohen, F. Medina, P. G. Frank, R. G. Pestell, D. Di Vizio, M. Loda, and M. P. Lisanti Caveolin-1 Promotes Tumor Progression in an Autochthonous Mouse Model of Prostate Cancer: GENETIC ABLATION OF Cav-1 DELAYS ADVANCED PROSTATE TUMOR DEVELOPMENT IN TRAMP MICE J. Biol. Chem., July 1, 2005; 280(26): 25134 - 25145. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. M. Williams and M. P. Lisanti Caveolin-1 in oncogenic transformation, cancer, and metastasis Am J Physiol Cell Physiol, March 1, 2005; 288(3): C494 - C506. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |